- Home
- LFVN vs PLRX Comparison
LFVN vs PLRX Comparison
Compare LFVN & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFVN | PLRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.1M | 71.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LFVN | PLRX |
|---|---|---|
| Price | $4.91 | $1.22 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.75 |
| AVG Volume (30 Days) | 332.6K | ★ 896.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.64% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.60 | N/A |
| P/E Ratio | $8.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.90 | $1.09 |
| 52 Week High | $19.28 | $3.46 |
Technical Indicators
Market Signals| Indicator | LFVN | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 37.71 | 50.20 |
| Support Level | $4.77 | $1.10 |
| Resistance Level | $5.32 | $1.22 |
| Average True Range (ATR) | 0.42 | 0.07 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 46.12 | 66.67 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.